REFERENCES
1. Pezzuto F, Buonaguro L, Buonaguro FM, Tornesello ML. Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma. Infect Agent Cancer 2017;12:27.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
5. Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol 2018;19:222-32.
6. Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 2015;149:1226-39.e4.
7. Kawai-Kitahata F, Asahina Y, Tanaka S, Kakinuma S, Murakawa M, et al. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features. J Gastroenterol 2016;51:473-86.
8. Totoki Y, Tatsuno K, Covington KR, Ueda H, Creighton CJ, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet 2014;46:1267-73.
9. Liu L, Lai S, Andrews LG, Tollefsbol TO. Genetic and epigenetic modulation of telomerase activity in development and disease. Gene 2004;340:1-10.
10. Lendvay TS, Morris DK, Sah J, Balasubramanian B, Lundblad V. Senescence mutants of Saccharomyces cerevisiae with a defect in telomere replication identify three additional EST genes. Genetics 1996;144:1399-412.
11. Lingner J, Cech TR. Purification of telomerase from Euplotes aediculatus: requirement of a primer 3’ overhang. Proc Natl Acad Sci U S A 1996;93:10712-7.
12. Cukusic A, Skrobot Vidacek N, Sopta M, Rubelj I. Telomerase regulation at the crossroads of cell fate. Cytogenet Genome Res 2008;122:263-72.
13. Pestana A, Vinagre J, Sobrinho-Simoes M, Soares P. TERT biology and function in cancer: beyond immortalisation. J Mol Endocrinol 2017;58:R129-R46.
14. Low KC, Tergaonkar V. Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem Sci 2013;38:426-34.
15. Liu T, Yuan X, Xu D. Cancer-specific telomerase reverse transcriptase (TERT) promoter mutations: biological and clinical implications. Genes (Basel) 2016;7:E38.
16. Daniel M, Peek GW, Tollefsbol TO. Regulation of the human catalytic subunit of telomerase (hTERT). Gene 2012;498:135-46.
17. Poole JC, Andrews LG, Tollefsbol TO. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene 2001;269:1-12.
18. Greenberg RA, O’Hagan RC, Deng H, Xiao Q, Hann SR, et al. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 1999;18:1219-26.
19. Oh S, Song YH, Yim J, Kim TK. Identification of Mad as a repressor of the human telomerase (hTERT) gene. Oncogene 2000;19:1485-90.
20. Cerezo A, Kalthoff H, Schuermann M, Schafer B, Boukamp P. Dual regulation of telomerase activity through c-Myc-dependent inhibition and alternative splicing of hTERT. J Cell Sci 2002;115:1305-12.
21. Dwyer JM, Liu JP. Ets2 transcription factor, telomerase activity and breast cancer. Clin Exp Pharmacol Physiol 2010;37:83-7.
22. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, et al. Direct activation of TERT transcription by c-MYC. Nat Genet 1999;21:220-4.
23. Kanaya T, Kyo S, Hamada K, Takakura M, Kitagawa Y, et al. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin Cancer Res 2000;6:1239-47.
24. Akincilar SC, Khattar E, Boon PL, Unal B, Fullwood MJ, et al. Long-range chromatin interactions drive mutant TERT promoter activation. Cancer Discov 2016;6:1276-91.
25. Barthel FP, Wei W, Tang M, Martinez-Ledesma E, Hu X, et al. Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet 2017;49:349-57.
26. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, et al. Highly recurrent TERT promoter mutations in human melanoma. Science 2013;339:957-9.
27. Alexiadis M, Rowley SM, Chu S, Leung DTH, Stewart CJR, et al. Mutational landscape of ovarian adult granulosa cell tumors from whole exome and targeted TERT promoter sequencing. Mol Cancer Res 2019;17:177-85.
28. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 2013;110:6021-6.
29. Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 2013;126:907-15.
30. Allory Y, Beukers W, Sagrera A, Flandez M, Marques M, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 2014;65:360-6.
31. Borah S, Xi L, Zaug AJ, Powell NM, Dancik GM, et al. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science 2015;347:1006-10.
32. Heidenreich B, Nagore E, Rachakonda PS, Garcia-Casado Z, Requena C, et al. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nat Commun 2014;5:3401.
33. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013;339:959-61.
34. Hurst CD, Platt FM, Knowles MA. Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. Eur Urol 2014;65:367-9.
35. Remke M, Ramaswamy V, Peacock J, Shih DJ, Koelsche C, et al. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol 2013;126:917-29.
36. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun 2013;4:2185.
37. Wu S, Huang P, Li C, Huang Y, Li X, et al. Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study. Eur Urol 2014;65:274-7.
38. Campos MA, Macedo S, Fernandes M, Pestana A, Pardal J, et al. TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma. J Am Acad Dermatol 2019;80:660-9.e6.
39. Lee HW, Park TI, Jang SY, Park SY, Park WJ, et al. Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e5766.
40. Cevik D, Yildiz G, Ozturk M. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. World J Gastroenterol 2015;21:311-7.
41. Lee SE, Chang SH, Kim WY, Lim SD, Kim WS, et al. Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma. Oncotarget 2016;7:69267-75.
42. Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 2013;4:2218.
43. Huang W, Zhou W, Li C, Yang Y, Shang YK, et al. Promoter mutations and cellular distribution of telomerase in non-clear cell and clear cell hepatocellular carcinoma. Oncotarget 2017;8:26288-97.
44. Yang XJ, Guo XC, Chen Y, Chen GR, Ma Y, et al. Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma. Oncotarget 2016;7:27838-47.
45. Chen YL, Jeng YM, Chang CN, Lee HJ, Hsu HC, et al. TERT promoter mutation in resectable hepatocellular carcinomas: a strong association with hepatitis C infection and absence of hepatitis B infection. Int J Surg 2014;12:659-65.
46. Yuan XT, Cheng GH, Yu JY, Zheng SZ, Sun C, et al. The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma. Oncotarget 2017;8:23120-9.
47. Pezzuto F, Izzo F, Buonaguro L, Annunziata C, Tatangelo F, et al. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma. Oncotarget 2016;7:54253-62.
48. Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu; Cancer Genome Atlas Research Network. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell 2017;169:1327-41.e23.
49. Nishida N, Nishimura T, Kaido T, Minaga K, Yamao K, et al. Molecular scoring of hepatocellular carcinoma for predicting metastatic recurrence and requirements of systemic chemotherapy. Cancers (Basel) 2018;10:E367.
50. Eichenmuller M, Trippel F, Kreuder M, Beck A, Schwarzmayr T, et al. The genomic landscape of hepatoblastoma and their progenies with HCC-like features. J Hepatol 2014;61:1312-20.
51. Fujimoto A, Furuta M, Totoki Y, Tsunoda T, Kato M, et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet 2016;48:500.
52. Nault JC, Calderaro J, Di Tommaso L, Balabaud C, Zafrani ES, et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology 2014;60:1983-92.
53. Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouze E, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol 2017;67:727-38.
54. Donati B, Pietrelli A, Pingitore P, Dongiovanni P, Caddeo A, et al. Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Cancer Med 2017;6:1930-40.
55. Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol 2014;20:12945-55.
56. Ki Kim S, Ueda Y, Hatano E, Kakiuchi N, Takeda H, et al. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma. Int J Cancer 2016;139:2512-8.
57. Jiao J, Watt GP, Stevenson HL, Calderone TL, Fisher-Hoch SP, et al. Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: prevalence and risk factors. Hepatol Commun 2018;2:718-31.
58. Jiang Z, Jhunjhunwala S, Liu J, Haverty PM, Kennemer MI, et al. The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res 2012;22:593-601.
59. Khoury JD, Tannir NM, Williams MD, Chen Y, Yao H, et al. Landscape of DNA virus associations across human malignant cancers: analysis of 3,775 cases using RNA-Seq. J Virol 2013;87:8916-26.
60. Paterlini-Brechot P, Saigo K, Murakami Y, Chami M, Gozuacik D, et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 2003;22:3911-6.
61. Tornesello ML, Buonaguro L, Izzo F, Buonaguro FM. Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget 2016;7:25087-102.
62. Kaslow DC, Black S, Bloom DE, Datla M, Salisbury D, et al. Vaccine candidates for poor nations are going to waste. Nature 2018;564:337-9.
63. Yang X, Wu L, Lin J, Wang A, Wan X, et al. Distinct hepatitis B virus integration patterns in hepatocellular carcinoma and adjacent normal liver tissue. Int J Cancer 2017;140:1324-30.
64. Ferber MJ, Montoya DP, Yu C, Aderca I, McGee A, et al. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 2003;22:3813-20.
65. Sung WK, Zheng H, Li S, Chen R, Liu X, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet 2012;44:765-9.
66. Gozuacik D, Murakami Y, Saigo K, Chami M, Mugnier C, et al. Identification of human cancer-related genes by naturally occurring hepatitis B virus DNA tagging. Oncogene 2001;20:6233-40.
67. Ding D, Lou X, Hua D, Yu W, Li L, et al. Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing-based approach. PLoS Genet 2012;8:e1003065.
68. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 2012;44:760-4.
69. Li W, Zeng X, Lee NP, Liu X, Chen S, et al. HIVID: an efficient method to detect HBV integration using low coverage sequencing. Genomics 2013;102:338-44.
70. Toh ST, Jin Y, Liu LZ, Wang JB, Babrzadeh F, et al. Deep sequencing of the hepatitis B virus in hepatocellular carcinoma patients reveals enriched integration events, structural alterations and sequence variations. Carcinogenesis 2013;34:787-98.
71. Lau CC, Sun T, Ching AK, He M, Li JW, et al. Viral-human chimeric transcript predisposes risk to liver cancer development and progression. Cancer Cell 2014;25:335-49.
72. Saitta C, Tripodi G, Barbera A, Bertuccio A, Smedile A, et al. Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma. Liver Int 2015;35:2311-7.
73. Yan H, Yang Y, Zhang L, Tang G, Wang Y, et al. Characterization of the genotype and integration patterns of hepatitis B virus in early- and late-onset hepatocellular carcinoma. Hepatology 2015;61:1821-31.
74. Chiu YT, Wong JK, Choi SW, Sze KM, Ho DW, et al. Novel pre-mRNA splicing of intronically integrated HBV generates oncogenic chimera in hepatocellular carcinoma. J Hepatol 2016;64:1256-64.
75. Zhao LH, Liu X, Yan HX, Li WY, Zeng X, et al. Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma. Nat Commun 2016;7:12992.
76. Lee WY, Bachtiar M, Choo CCS, Lee CG. Comprehensive review of hepatitis B virus-associated hepatocellular carcinoma research through text mining and big data analytics. Biol Rev Camb Philos Soc 2018; doi: 10.1111/brv.12457.
77. Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 2015;47:505-11.
78. Iliopoulos D, Satra M, Drakaki A, Poultsides GA, Tsezou A. Epigenetic regulation of hTERT promoter in hepatocellular carcinomas. Int J Oncol 2009;34:391-9.
79. Kumakura S, Tsutsui TW, Yagisawa J, Barrett JC, Tsutsui T. Reversible conversion of immortal human cells from telomerase-positive to telomerase-negative cells. Cancer Res 2005;65:2778-86.
80. Widschwendter A, Muller HM, Hubalek MM, Wiedemair A, Fiegl H, et al. Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecol Oncol 2004;93:407-16.
81. Guilleret I, Benhattar J. Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression and telomerase activity and shortened telomeres. Exp Cell Res 2003;289:326-34.
82. Guilleret I, Yan P, Grange F, Braunschweig R, Bosman FT, et al. Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int J Cancer 2002;101:335-41.
83. Dessain SK, Yu H, Reddel RR, Beijersbergen RL, Weinberg RA. Methylation of the human telomerase gene CpG island. Cancer Res 2000;60:537-41.
84. Zhang H, Weng X, Ye J, He L, Zhou D, et al. Promoter hypermethylation of TERT is associated with hepatocellular carcinoma in the Han Chinese population. Clin Res Hepatol Gastroenterol 2015;39:600-9.
85. Li Y, Zhou QL, Sun W, Chandrasekharan P, Cheng HS, et al. Non-canonical NF-kappaB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation. Nat Cell Biol 2015;17:1327-38.
86. Bell RJ, Rube HT, Kreig A, Mancini A, Fouse SD, et al. Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 2015;348:1036-9.
87. Liu X, Bishop J, Shan Y, Pai S, Liu D, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 2013;20:603-10.
88. Xing M, Liu R, Liu X, Murugan AK, Zhu G, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 2014;32:2718-26.
89. Macerola E, Loggini B, Giannini R, Garavello G, Giordano M, et al. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. Virchows Arch 2015;467:177-84.
90. Liu R, Bishop J, Zhu G, Zhang T, Ladenson PW, et al. Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality. JAMA Oncol 2016; doi: 10.1001/jamaoncol.2016.3288.
92. Nagore E, Heidenreich B, Rachakonda S, Garcia-Casado Z, Requena C, et al. TERT promoter mutations in melanoma survival. Int J Cancer 2016;139:75-84.
93. Liu R, Zhang T, Zhu G, Xing M. Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer. Nat Commun 2018;9:579.
94. Pilati C, Letouze E, Nault JC, Imbeaud S, Boulai A, et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell 2014;25:428-41.
95. Ko E, Seo HW, Jung ES, Kim BH, Jung G. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer. Oncotarget 2016;7:684-99.
96. Ding D, Xi P, Zhou J, Wang M, Cong YS. Human telomerase reverse transcriptase regulates MMP expression independently of telomerase activity via NF-kappaB-dependent transcription. FASEB J 2013;27:4375-83.
97. Park JI, Venteicher AS, Hong JY, Choi J, Jun S, et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 2009;460:66-72.
98. Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, et al. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998;396:84-8.
99. Li X, Xu W, Kang W, Wong SH, Wang M, et al. Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features. Theranostics 2018;8:1740-51.
100. Dhanasekaran R, Nault JC, Roberts LR, Zucman-Rossi J. Genomic medicine and implications for hepatocellular carcinoma prevention and therapy. Gastroenterology 2019;156:492-509.
101. Mizukoshi E, Nakagawa H, Kitahara M, Yamashita T, Arai K, et al. Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma. Cancer Lett 2015;364:98-105.
